UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pulmonary hypertension in patients with left heart failure

Authors
Udhay Krishnan, MD
Evelyn Horn, MD
Section Editor
Barry A Borlaug, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC

INTRODUCTION

Left-sided heart failure (left heart disease or LHD) is the most common cause of pulmonary hypertension (PH). This form of PH (henceforth described as PH due to left heart disease [PH-LHD]) can occur in patients with heart failure with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or HF caused by left-sided valvular disease. Recognition of PH-LHD is important because it is clearly associated with increased morbidity and mortality [1-7]; however, therapeutic strategies beyond treatment of the underlying LHD have not been well-established.

The prevalence, pathogenesis, evaluation, prognosis, and treatment of PH-LHD are discussed here. Evaluation and management of patients with HF are discussed separately. (See "Evaluation of the patient with suspected heart failure" and "Determining the etiology and severity of heart failure or cardiomyopathy" and "Clinical manifestations and diagnosis of heart failure with preserved ejection fraction" and "Overview of the therapy of heart failure with reduced ejection fraction" and "Treatment and prognosis of heart failure with preserved ejection fraction".)

CLASSIFICATION AND DEFINITIONS

The World Health Organization has categorized PH, clinically, into five groups based on the underlying etiology for the disease [3]. When all five groups are described collectively, the term PH is used. The term pulmonary arterial hypertension is used when referring to patients in group 1. Group 2 consists of patients with PH due to left heart disease (PH-LHD). A more detailed description of the classification of PH is discussed separately. (See "Classification and prognosis of pulmonary hypertension in adults", section on 'Classification'.)

PH has been defined as a resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg on right heart catheterization. PH-LHD is defined hemodynamically as an mPAP ≥25 mmHg and a pulmonary capillary wedge pressure (PCWP) ≥15 mmHg [8].

PH-LHD has been characterized by various descriptors in the medical literature with subsequent adoption of more standardized definitions. Older terms have included pulmonary venous hypertension, out-of-proportion PH, mixed PH, and passive versus reactive PH. This confusing terminology stems from the complex nature of PH-LHD, which encompasses both patients with elevated mPAP from passive transmission of increased left-sided filling pressures to the pulmonary circulation, as well as patients with superimposed pulmonary vascular disease. The recommended nomenclature to describe these two subgroups, respectively, are isolated post-capillary PH and combined post- and precapillary PH [9], as described below. (See 'Right heart catheterization' below.)

                       
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Oct 02, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663.
  2. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183.
  3. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34.
  4. Clark CB, Horn EM. Group 2 Pulmonary Hypertension: Pulmonary Venous Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 2016; 34:401.
  5. Rosenkranz S, Gibbs JS, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37:942.
  6. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119.
  7. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail 2013; 1:290.
  8. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.
  9. Vachiéry JL, Adir Y, Barberà JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62:D100.
  10. Weitsman T, Weisz G, Farkash R, et al. Pulmonary Hypertension with Left Heart Disease: Prevalence, Temporal Shifts in Etiologies and Outcome. Am J Med 2017.
  11. Khush KK, Tasissa G, Butler J, et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J 2009; 157:1026.
  12. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4:257.
  13. Gerges M, Gerges C, Pistritto AM, et al. Pulmonary Hypertension in Heart Failure. Epidemiology, Right Ventricular Function, and Survival. Am J Respir Crit Care Med 2015; 192:1234.
  14. Hart SA, Krasuski RA, Wang A, et al. Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis. J Heart Valve Dis 2010; 19:708.
  15. Raina A, Gertz ZM, O'Donnell WT, et al. Pulmonary hypertension is a manifestation of congestive heart failure and left ventricular diastolic dysfunction in octogenarians with severe aortic stenosis. Pulm Circ 2015; 5:521.
  16. Alexopoulos D, Lazzam C, Borrico S, et al. Isolated chronic mitral regurgitation with preserved systolic left ventricular function and severe pulmonary hypertension. J Am Coll Cardiol 1989; 14:319.
  17. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 2013; 143:758.
  18. Tedford RJ, Hassoun PM, Mathai SC, et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012; 125:289.
  19. Kulik TJ. Pulmonary hypertension caused by pulmonary venous hypertension. Pulm Circ 2014; 4:581.
  20. Houston B, Hsu S, Tampakakis E, Tedford R. The Right Ventricle: A Not-So-Innocent Bystander in Pulmonary Hypertension Due to Left Heart Disease. Adv Pulm Hypert 2015; 14:79.
  21. Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3452.
  22. Assad TR, Hemnes AR, Larkin EK, et al. Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. J Am Coll Cardiol 2016; 68:2525.
  23. Leopold JA. Biological Phenotyping of Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension: Focus on Pulmonary Vascular Remodeling. J Am Coll Cardiol 2016; 68:2537.
  24. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41:217.
  25. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42.
  26. Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014; 7:116.
  27. Opotowsky AR, Ojeda J, Rogers F, et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging 2012; 5:765.
  28. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33:189.
  29. Reddy YN, Melenovsky V, Redfield MM, et al. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol 2016; 68:473.
  30. Miller WL, Mahoney DW, Enriquez-Sarano M. Quantitative Doppler-echocardiographic imaging and clinical outcomes with left ventricular systolic dysfunction: independent effect of pulmonary hypertension. Circ Cardiovasc Imaging 2014; 7:330.
  31. Tedford RJ, Beaty CA, Mathai SC, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant 2014; 33:289.
  32. Tampakakis E, Leary PJ, Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 2015; 3:9.
  33. Fawzy ME, Hassan W, Stefadouros M, et al. Prevalence and fate of severe pulmonary hypertension in 559 consecutive patients with severe rheumatic mitral stenosis undergoing mitral balloon valvotomy. J Heart Valve Dis 2004; 13:942.
  34. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 2004; 25:971.
  35. Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130:2310.
  36. Hoeper MM, Meyer K, Rademacher J, et al. Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2016; 4:441.
  37. Melenovsky V, Andersen MJ, Andress K, et al. Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 2015; 17:1161.
  38. Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 2005; 27:222.
  39. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1:213.
  40. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134:44.
  41. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85:195.
  42. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005; 11:12.
  43. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555.
  44. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459.
  45. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124:164.
  46. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309:1268.
  47. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36:2565.
  48. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128:502.
  49. Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19:48.
  50. Kulkarni A, Singh TP, Sarnaik A, et al. Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 2004; 23:1441.